Element Capital Management LLC Purchases Shares of 4,265 Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Element Capital Management LLC bought 4,265 shares of Regeneron Pharmaceuticals, valued at approximately $2.7 million, signaling growing interest from institutional investors.
• Several hedge funds have increased their stakes in Regeneron, with Aberdeen Group plc boosting its position by 30.1%, reflecting strong institutional confidence in the company.
• Regeneron Pharmaceuticals reported earnings of $12.89 per share for the last quarter, significantly exceeding the expected $8.43, with a revenue increase of 3.6% year-over-year.

Element Capital Management LLC bought a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 4,265 shares of the biopharmaceutical company's stock, valued at approximately $2,705,000.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Vanguard Group Inc. lifted its stake in Regeneron Pharmaceuticals by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 9,407,891 shares of the biopharmaceutical company's stock valued at $5,966,767,000 after acquiring an additional 121,545 shares during the period. Capital International Investors lifted its stake in shares of Regeneron Pharmaceuticals by 41.6% in the 4th quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company's stock worth $3,373,859,000 after purchasing an additional 1,390,534 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in shares of Regeneron Pharmaceuticals by 63.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company's stock worth $1,485,527,000 after buying an additional 810,144 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 18.0% in the first quarter. Goldman Sachs Group Inc. now owns 1,143,093 shares of the biopharmaceutical company's stock worth $724,984,000 after buying an additional 174,056 shares during the last quarter. Finally, Northern Trust Corp boosted its holdings in shares of Regeneron Pharmaceuticals by 14.8% in the fourth quarter. Northern Trust Corp now owns 1,054,829 shares of the biopharmaceutical company's stock worth $751,386,000 after buying an additional 136,184 shares during the last quarter. Institutional investors own 83.31% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on REGN shares. Wells Fargo & Company downgraded shares of Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 price objective on the stock. in a report on Friday, August 1st. Royal Bank Of Canada raised their target price on shares of Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the stock a "sector perform" rating in a research note on Monday, August 4th. UBS Group restated a "neutral" rating on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. Guggenheim raised their target price on shares of Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the stock a "buy" rating in a research note on Friday, August 1st. Finally, Truist Financial decreased their target price on shares of Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating on the stock in a research note on Monday, August 11th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $829.65.

Regeneron Pharmaceuticals Price Performance

REGN traded down $2.13 during trading hours on Tuesday, hitting $571.78. The company's stock had a trading volume of 852,619 shares, compared to its average volume of 1,107,271. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $1,211.20. The stock has a market cap of $60.60 billion, a price-to-earnings ratio of 14.41, a P/E/G ratio of 1.93 and a beta of 0.33. The business's 50-day moving average price is $545.33 and its 200-day moving average price is $593.59. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, topping analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The business had revenue of $3,675,600 billion during the quarter, compared to analysts' expectations of $3.30 billion. During the same period last year, the company posted $11.56 EPS. The business's revenue was up 3.6% on a year-over-year basis. Sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Monday, August 18th will be paid a $0.88 dividend. The ex-dividend date of this dividend is Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio is 8.87%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.